Ryan Scott

Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Poorer outcomes were shown in Black patients with hormone receptor-positive breast cancer, including in patients with similar 21-gene recurrence scores.

Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.

Sacituzumab govitecan-hziy vs single-agent docetaxel with be evaluated in the phase 3 EVOKE-01 trial of patients with metastatic non–small cell lung cancer.

The positive results from EQUTE informed the doses that will be evaluated in the phase 3 EQUATOR trial of tolizumab versus placebo in combination with corticosteroids as a first-line treatment in patients with acute graft-versus-host disease.

Association between itolizumab serum concentrations and clinical response have been identified in patients with acute graft-versus-host disease treated in the phase 1b EQUATE study.

Four-year follow-up data from the KEYNOTE-042 show promising survival and durable response in patients with non–small cell lung cancer.

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.